GlaxoSmithKline and AstraZeneca both reported trial results that will likely mak...
BARCELONA - GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.
AstraZeneca and its U.S. development partner Merck & Co said their Lynparza drug cut the risk of the cancer progressing again by 41%. The figure was 38% for GSK’s drug. But different trial settings will make it difficult to predict how physicians will weigh up the two drugs. Both companies, which are competing to burnish their oncology credentials, showed that not just the small group of women with mutated BRCA genes can benefit as the results also covered the full variety of ovarian cancer.
But in a patient subgroup with tumors where the DNA repair was still intact, GSK appears to make headway over its rivals. “We know now we can use PARP inhibitors in the first-line setting beyond women with BRCA mutations,” said Susana Banerjee, an oncologist at the Royal Marsden NHS Foundation Trust in London, who discussed the results at an ESMO press conference.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Largest health care scam ever: Fake genetic testing result scheme results in $2.1 billion in Medicaid lossesA fraudulent cancer screening system resulted in Medicare being being billed for over $2.1 billion in unnecessary costs, and, with 35 arrested, has become the 'largest health care scam ever' according to the government.
Baca lebih lajut »
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug useGlaxoSmithKline and AstraZeneca both reported trial results that will likely mak...
Baca lebih lajut »
A viral fake news story linked trans health care to “thousands” of deathsHormone blockers used by some transgender people have multiple uses, including treating prostate cancer in terminally ill patients.
Baca lebih lajut »
Heartburn Drugs and Cancer: What Are the Risks?FDA testing found the impurity in generic versions and in brand-name Zantac. Already, one major manufacturer has recalled its version of the drug, and another has ceased distribution.
Baca lebih lajut »
Amazon Everywhere Has Different Ring NowAmazon is scaling up its tech hardware portfolio. WSJheard breaks down how the e-commerce giant has been able to stay competitive despite questions around the scope of its influence. WSJWhatsNow
Baca lebih lajut »
FDA Expanding Recall of Widely-Used Blood Pressure Drug | HealthyWomenIf you take medication for your blood pressure, pay attention. Torrent Pharmaceuticals told the Food and Drug Administration (FDA) late last week that it was expanding its recall to three additional lots of Losartan potassium tablets and two
Baca lebih lajut »